{"entity":{"id":"nct06974929","kind":"trial","name":"A Clinical Study of HRS-6209 Combined With Other Treatment Regimens in Patients With Breast Cancer","aka":[],"tldr":"A phase 1/2 trial of HRS-6209 Capsules in advanced solid tumours, run by Jiangsu HengRui Medicine Co., Ltd., now recruiting.","summary":"A Clinical Study of HRS-6209 Combined With Other Treatment Regimens in Patients With Breast Cancer is a phase 1/2 interventional study registered as NCT06974929 by Jiangsu HengRui Medicine Co., Ltd., with 80 participants planned, started 2025-05-22 and due to reach its primary completion in 2026-12. Interventions recorded: HRS-6209 Capsules, Letrozole Tablets and HRS-2189 Tablets.","status":"recruiting","asOf":"2026-09-16","links":[{"label":"ClinicalTrials.gov NCT06974929","url":"https://clinicaltrials.gov/study/NCT06974929"}],"tags":["pipeline","ctgov-ingest"],"related":[],"cancers":["metastatic-cancer"],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":["hengrui"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"notes":[],"nct":"NCT06974929","phase":"1/2","setting":"An Open-Label, Multicenter Phase Ib/II Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of HRS-6209 Combination Therapy in Patients With Breast Cancer","sponsor":"Jiangsu HengRui Medicine Co., Ltd.","enrolled":80,"outcomes":[]},"route":"/trials/nct06974929/","neighbours":{"cancer":[{"id":"metastatic-cancer","kind":"cancer","name":"Metastatic cancer (cancer that has spread)","route":"/cancers/metastatic-cancer/"}],"company":[{"id":"hengrui","kind":"company","name":"Jiangsu Hengrui Pharmaceuticals","route":"/companies/hengrui/"}]}}